Among patients with stable coronary artery disease (CAD), angina with or without evidence of myocardial ischemia is associated with worse clinical outcomes, but silent ischemia is not, according to a ...

For patients with moderate-to-severe ischemia but without obstructive coronary disease, the so-called INOCA patient, there is no correlation between the severity of ischemia on stress echocardiography ...

Calgary, Alberta--(Newsfile Corp. - September 16, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PCI improved angina symptoms at 12 weeks vs. a sham ...

Please provide your email address to receive an email when new articles are posted on . Despite having less ischemia and less extensive CAD compared with men, women had more frequent angina, according ...

Sir, you are no longer a maverick. We should have listened to you. It took over 40 years, but today, at the American Heart Association (AHA) Scientific Sessions 2019, we learned that you were right to ...

An acute MI may be the initial clinical manifestation of CAD in elderly persons, although many elderly persons experience myocardial ischemia for years prior to an acute MI. Unfortunately, due to the ...

Percutaneous coronary intervention (PCI) is frequently performed to reduce the symptoms of stable angina. Whether PCI relieves angina more than a placebo procedure in patients who are not receiving ...

SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, ...

Advances in pharmacotherapy for stable angina have produced a wide choice of drugs with various mechanisms of action, potentially enabling individualized, patient-specific treatment strategies to be ...

- Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory ...